The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2, influenza virus and RSV. The investigators will include app. 320 participants which will be followed for up to 17 months. During this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with SARS-CoV-2, influenza virus or RSV. Participants are invited to take a test for SARS-CoV-2, influenza virus or RSV in case of respiratory symptoms. If participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. The investigators will also record the duration and strength of the following symptoms: * Cough * Fever * Tired * Sore throat * Difficulty breathing * Respiratory distress * Headache * Loss (or alteration) of smell * Loss (or alteration) of sense of taste * Myalgias * Chills * Subjective fever * Pink sputum (or coughing up blood) * Thoracic pain * Runny nose * Abdominal pain * Nausea * Vomiting * Diarrhea * Constipation * Irritated or watery eyes * Rashes * Other
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
SARS-CoV-2 infectious viral load
Timeframe: up to 14 days post symptom onset